Basiliximab Biosimilar – Anti-IL2RA, CD25 mAb – Research Grade

Description of Basiliximab Biosimilar - Anti-IL2RA, CD25 mAb - Research Grade

Basiliximab Biosimilar – Anti-IL2RA, CD25 mAb – Research Grade Basiliximab Biosimilar – Anti-IL2RA, CD25 mAb – Research Grade Introduction

Basiliximab Biosimilar is an antibody drug that specifically targets the interleukin-2 receptor alpha (IL2RA) protein. It is a monoclonal antibody (mAb) that is designed to mimic the function of basiliximab, a FDA-approved drug for preventing organ rejection in transplant patients. This biosimilar version is produced using recombinant DNA technology and has been extensively researched for its structure, activity, and potential applications in the field of immunology.

Structure of Basiliximab Biosimilar

Basiliximab Biosimilar is a humanized IgG1 kappa monoclonal antibody with a molecular weight of approximately 145 kDa. It is composed of two heavy chains and two light chains, each containing four constant domains and one variable domain. The variable domains are responsible for binding to the IL2RA protein, while the constant domains provide stability and effector functions.

Activity of Basiliximab Biosimilar

The primary function of Basiliximab Biosimilar is to block the IL2RA protein, which is expressed on the surface of activated T cells. This protein is essential for the activation and proliferation of T cells, which play a crucial role in immune response. By binding to IL2RA, Basiliximab Biosimilar prevents the activation and proliferation of T cells, thereby suppressing the immune response. This activity is important in preventing organ rejection in transplant patients and also in treating autoimmune diseases where the immune system attacks the body’s own tissues.

Applications of Basiliximab Biosimilar Preventing organ rejection

Basiliximab Biosimilar is primarily used in the prevention of organ rejection in transplant patients. When an organ is transplanted into a person, the body’s immune system recognizes it as foreign and tries to attack it. This can lead to organ rejection and failure. By blocking the IL2RA protein, Basiliximab Biosimilar helps to suppress the immune response and prevent rejection of the transplanted organ.

Treating autoimmune diseases

Autoimmune diseases occur when the immune system mistakenly attacks and damages the body’s own tissues. By targeting the IL2RA protein, Basiliximab Biosimilar can help to suppress the immune response and reduce the symptoms of autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.

Research use

Basiliximab Biosimilar is also widely used in research to study the role of IL2RA in various diseases and to develop new treatments. Its high specificity and potency make it a valuable tool for studying the immune system and its functions.

Conclusion

Basiliximab Biosimilar is a promising antibody drug that targets the IL2RA protein and has potential applications in preventing organ rejection and treating autoimmune diseases. Its well-defined structure and specific activity make it a valuable tool for research in the field of immunology. With further studies and clinical trials, this biosimilar has the potential to improve the lives of transplant patients and individuals with autoimmune diseases.

Keywords: antibody, therapeutic target, basiliximab biosimilar, IL2RA protein, monoclonal antibody, organ rejection, autoimmune diseases, research.